Gene Therapy Market Report

Gene Therapy Market Analysis By Product Type (instruments, reagents, vectors), By Indication (Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorder), By Commercialized Therapies (Gendicine, Rexin-G) 2014 To 2025

Format: PDF  |  Report ID: GVR4223

Gene therapy is a rapidly developing field of medicine wherein genes are introduced into the body to treat diseases. Gene therapyis the therapeutic delivery ofnucleic acidpolymersinto a patient's cells as adrugto treat disease.Genes govern heredity and deliver the basic biological code for determining a cell's specific functions. Gene therapy pursues to offer genes that correct or supply the disease-controlling functions of cells.

Gene therapy consists of basically two types of methods; namely the Somatic gene therapy that introduces therapeutic genes at the tissue or cellular level to treat a specific individual and the other is the Germ-line gene therapythat inserts genes into reproductive cells or possibly into embryos to correct genetic defects that could be passed on to future generations.

In simple words,gene therapy is an approach to repair a genetic problem at its source. The polymers are eithertranslatedintoproteins, interfere with targetgene expression, or possibly correctmutations. The most common form usesDNAthat encodes a functional, therapeuticgeneto replace amutatedgene. The polymer molecule is packaged within a "vector", which carries the molecule inside cells of the body.

The factors that propel the growth of the global Gene Therapy Marketinclude rising frequencies of chronic diseases all over the world, unconventional stage of clinical studies,absence of cure for cancer, and increasing R&D activities.

On the other hand, there are also factors that hamper the growth of the market such as high expenditure on the gene therapy drugs and inflexible regulatory authorization process for gene therapy.

The global Gene Therapy Market is categorized on the basis of product type, indication, commercializedtherapies, and geography.

On the basis of product type, the global Gene Therapy Market is categorizedas instruments, reagents,physical methods of gene transfer, and vectors. The vectors are further categorized as Adenovirus, Retrovirus, Plasmid DNA, and others. The physical methods of gene transfer include electroporation, hydrodynamic, microinjection, particle bombardment, and ultrasound-mediated transfection.

On the basis of indication, the global Gene Therapy Market is categorizedas Oncology, Cardiovascular Diseases, Infectious Diseases, Neurological Disorder, Genetic Diseases, and others. The oncology sector dominates the Gene Therapy Market due to focus on treatment and cure of cancer by various research institutes as well as pharmaceutical companies.

On the basis of commercializedtherapies, the global Gene Therapy Market is categorized asGlybera, Neovasculogen, Gendicine, Rexin-G, and Oncorine.

On the basis of geography, the global Gene Therapy Market is categorizedas North America, Europe, Asia Pacific, and Rest of the World. The Gene Therapy Market is dominated by North America and accounts for the largest market share. One of the remarkable events is that the gene therapy clinical trials all over the globe were first initiated in the United States of America.

Additionally, the National Institutes of Health (NIH) of the United States is performing an imperative role; as it assembles a databank for all accomplished or enduring gene therapy trials, as a crucial source of information for trials executed in the U.S.Europe holds the second largest market share for gene therapy; whereas, Asia Pacific is anticipated to witness the highest growth of Gene Therapy Market in the coming years.

Some of the prominent players that fuel the growth of the global Gene Therapy Market include SibionoGeneTech Co. Ltd., Shanghai Sunway Biotech Co. Ltd, Human Stem Cells Institute, UniQure N.V, Spark Therapeutics, AnGes MG, Transgene, Urigen Pharmaceuticals, GenVec, Vical, BioSante Pharmaceuticals, Genzyme Corporation., LLC, AdvantageneInc, Bluebird Bio, Oxford BioMedica Plc, and Vical Inc.

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User - $5,950
Library Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Custom research service

    Custom research service

    Speak to the report author to design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service excellence represented in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • BOA